Denver Health and Hospital Authority, Denver, CO.
Department of Emergency Medicine, University of Colorado, Aurora, CO, USA.
Am J Health Syst Pharm. 2023 Aug 4;80(16):1039-1055. doi: 10.1093/ajhp/zxad108.
This article, the first in a 2-part review, aims to reinforce current literature on the pathophysiology of cardiac arrhythmias and various evidence-based treatment approaches and clinical considerations in the acute care setting. Part 1 of this series focuses on atrial arrhythmias.
Arrhythmias are prevalent throughout the world and a common presenting condition in the emergency department (ED) setting. Atrial fibrillation (AF) is the most common arrhythmia worldwide and expected to increase in prevalence. Treatment approaches have evolved over time with advances in catheter-directed ablation. Based on historic trials, heart rate control has been the long-standing accepted outpatient treatment modality for AF, but the use of antiarrhythmics is often still indicated for AF in the acute setting, and ED pharmacists should be prepared and poised to help in AF management. Other atrial arrhythmias include atrial flutter (AFL), atrioventricular nodal reentry tachycardia (AVNRT), and atrioventricular reentrant tachycardia (AVRT), which warrant distinction due to their unique pathophysiology and because each requires a different approach to utilization of antiarrhythmics. Atrial arrhythmias are typically associated with greater hemodynamic stability than ventricular arrhythmias but still require nuanced management according to patient subset and risk factors. Since antiarrhythmics can also be proarrhythmic, they may destabilize the patient due to adverse effects, many of which are the focus of black-box label warnings that can be overreaching and limit treatment options. Electrical cardioversion for atrial arrhythmias is generally successful and, depending on the setting and/or hemodynamics, often indicated.
Atrial arrhythmias arise from a variety of mechanisms, and appropriate treatment depends on various factors. A firm understanding of physiological and pharmacological concepts serves as a foundation for exploring evidence supporting agents, indications, and adverse effects in order to provide appropriate care for patients.
本文是 2 部分综述的第 1 部分,旨在强化当前关于心律失常的病理生理学以及在急症护理环境中的各种循证治疗方法和临床注意事项的文献。本系列的第 1 部分重点介绍房性心律失常。
心律失常在全球范围内普遍存在,也是急诊科(ED)常见的就诊病症。房颤(AF)是全球最常见的心律失常,预计其发病率将会上升。随着导管消融技术的进步,治疗方法也在不断发展。基于历史研究,AF 的长期标准门诊治疗模式一直是心率控制,但在急性情况下,AF 仍常需使用抗心律失常药物,ED 药剂师应做好准备并随时准备协助 AF 管理。其他房性心律失常包括房扑(AFL)、房室结折返性心动过速(AVNRT)和房室折返性心动过速(AVRT),由于其独特的病理生理学,以及每种心律失常都需要采用不同的抗心律失常药物使用方法,因此需要加以区分。房性心律失常通常比室性心律失常具有更高的血液动力学稳定性,但仍需根据患者亚组和危险因素进行细致的管理。由于抗心律失常药物也可能导致心律失常,它们可能会因不良反应而使患者病情不稳定,其中许多不良反应都是黑框标签警告的重点,这些警告可能会过度概括并限制治疗选择。电复律通常可成功治疗房性心律失常,并且根据具体情况和/或血液动力学情况,通常需要进行电复律。
房性心律失常的发病机制多种多样,因此适当的治疗取决于多种因素。深入了解生理和药理学概念可以为探索支持药物、适应证和不良反应的证据奠定基础,从而为患者提供适当的治疗。